Last €72.85 EUR
Change Today +1.20 / 1.67%
Volume 600.0
As of 5:08 AM 09/16/14 All times are local (Market data is delayed by at least 15 minutes).

Audit Committee* - novartis ag-adr (NOTA)

Name (Connections)Board RelationshipsTitleKey Developments
Ulrich Lehner Ph.D. 173 RelationshipsVice Chairman, Independent Lead Director, Member of Audit & Compliance Committee, Member of Governance, Nomination & Corporate Responsibilities Committee and Member of Compensation Committee 
Enrico Vanni Ph.D. 35 RelationshipsVice Chairman, Chairman of Compensation Committee, Member of Audit & Compliance Committee and Member of Research & Development Committee 
Srikant Datar Ph.D. 61 RelationshipsNon-Executive Director, Chairman of Audit & Compliance Committee, Member of Compensation Committee and Member of Risk Committee 
Andreas von Planta Ph.D. 69 RelationshipsDirector, Chairman of Risk Committee, Member of Audit & Compliance Committee and Member of Governance, Nomination & Corporate Responsibilities Committee 

Compensation Committee* - novartis ag-adr (NOTA)

Name (Connections)Board RelationshipsTitle
Srikant Datar Ph.D. 61 RelationshipsNon-Executive Director, Chairman of Audit & Compliance Committee, Member of Compensation Committee and Member of Risk Committee
Ann Fudge 384 RelationshipsDirector, Member of Risk Committee, Member of Compensation Committee and Member of Governance, Nomination & Corporate Responsibilities Committee
Ulrich Lehner Ph.D. 173 RelationshipsVice Chairman, Independent Lead Director, Member of Audit & Compliance Committee, Member of Governance, Nomination & Corporate Responsibilities Committee and Member of Compensation Committee
Enrico Vanni Ph.D. 35 RelationshipsVice Chairman, Chairman of Compensation Committee, Member of Audit & Compliance Committee and Member of Research & Development Committee
NOTA Compensation vs. Industry
2.1M
429.1K
Chief Executive Officer
483.3K
270.7K
Chief Financial Officer
Share price activity for NOVARTIS AG-ADR (NOTA)
52 Week Price Performance
NOTA
Industry Average

Nominating Committee* - novartis ag-adr (NOTA)

Name (Connections)Board RelationshipsTitleKey Developments
Ulrich Lehner Ph.D. 173 RelationshipsVice Chairman, Independent Lead Director, Member of Audit & Compliance Committee, Member of Governance, Nomination & Corporate Responsibilities Committee and Member of Compensation CommitteeNovartis AG Appoints Bruno Strigini as President of Novartis Oncology
06/9/14
Pierre Landolt Ph.D. 26 RelationshipsIndependent & Non Executive Director and Chairman of Governance, Nomination & Corporate Responsibilities CommitteeNovartis AG Announces Executive Changes
04/24/13
Andreas von Planta Ph.D. 69 RelationshipsDirector, Chairman of Risk Committee, Member of Audit & Compliance Committee and Member of Governance, Nomination & Corporate Responsibilities CommitteeNovartis AG Announces Management Changes
01/23/13
Ann Fudge 384 RelationshipsDirector, Member of Risk Committee, Member of Compensation Committee and Member of Governance, Nomination & Corporate Responsibilities CommitteeNovartis AG Announces Resignation of Marjorie Yang from the Board of Directors
11/9/12

Corporate Governance Committee* - novartis ag-adr (NOTA)

Name (Connections)Board RelationshipsTitle
Ann Fudge 384 RelationshipsNon-Executive Director, Chairman of Audit & Compliance Committee, Member of Compensation Committee and Member of Risk Committee
Pierre Landolt Ph.D. 26 RelationshipsDirector, Member of Risk Committee, Member of Compensation Committee and Member of Governance, Nomination & Corporate Responsibilities Committee
Ulrich Lehner Ph.D. 173 RelationshipsVice Chairman, Independent Lead Director, Member of Audit & Compliance Committee, Member of Governance, Nomination & Corporate Responsibilities Committee and Member of Compensation Committee
Andreas von Planta Ph.D. 69 RelationshipsVice Chairman, Chairman of Compensation Committee, Member of Audit & Compliance Committee and Member of Research & Development Committee
NOTA and Competitor
Insiders vs. External
Board
0%
100%
Novartis AG
7%
93%
Gilead Sciences Inc.
17%
83%
The Procter & Gamble Company
7%
93%
Pfizer Inc.
8%
92%
Merck & Co. Inc.
9%
91%
Roche Holding AG
Insiders
External Board Members

Executive Committee* - novartis ag-adr (NOTA)

Name (Connections)Board RelationshipsTitle
Steven Baert 0 RelationshipsHead of Human Resources and Member of Executive Committee
Raymund Breu Ph.D. 36 RelationshipsFormer Chief Financial Officer
Jürgen Brokatzky-Geiger Ph.D. 6 RelationshipsGlobal Head of Corporate Responsibility
Kevin Buehler 14 RelationshipsFormer Division Head of Alcon and Member of Executive Committee
Felix Ehrat Ph.D. 5 RelationshipsGeneral Counsel, Member of Executive Committee and General Counsel of Novartis International Ag
David Epstein B.Sc., M.B.A. 0 RelationshipsDivision Head of Novartis Pharmaceuticals and Member of Executive Committee
Mark Fishman M.D. 0 RelationshipsPresident of Institutes for Biomedical Research (NIBR) and Member of Executive Committee
Richard Francis 0 RelationshipsDivision Head of Sandoz and Member of Executive Committee
Jeffrey George 5 RelationshipsDivision Head of Alcon and Member of Executive Committee
George Gunn BVM&S, DVSM, MRCVS. 0 RelationshipsDivision Head of Animal Health and Member of Executive Committee
Alexandre Jetzer 13 RelationshipsFormer Non-Executive Director and Member of Executive Committee
Joseph Jimenez MBA 16 RelationshipsChief Executive Officer and Member of Executive Committee
Harry Kirsch 0 RelationshipsChief Financial Officer and Member of Executive Committee
Brian McNamara 0 RelationshipsDivision Head of Novartis OTC and Member of Executive Committee
Andrin Oswald M.D. 0 RelationshipsDivision Head of Novartis Vaccines and Member of Executive Committee
Joerg Reinhardt Ph.D. 12 RelationshipsChairman and Chairman of Research & Development Committee
Jonathan Symonds CBE 59 RelationshipsFormer Advisor
Management Effectiveness Relative to the Industry
Return on Equity
0.5x
Return on Assets
0.7x
Return on Total Capital
0.6x
TEV/Total Revenue(LTM)
0.6x
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOTA:GR €72.85 EUR +1.20

NOTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $104.76 USD +3.77
Merck & Co Inc $59.99 USD +0.47
Pfizer Inc $30.05 USD +0.13
Roche Holding AG SFr.277.50 CHF +1.70
Procter & Gamble Co/The $84.08 USD +0.21
View Industry Companies
 

Industry Analysis

NOTA

Industry Average

Valuation NOTA Industry Range
Price/Earnings 25.2x
Price/Sales 3.9x
Price/Book 3.2x
Price/Cash Flow 26.0x
TEV/Sales 3.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.